TrialJournal of cellular physiology2016

Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.

Laura Pizzuti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.